-
Je něco špatně v tomto záznamu ?
Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes
Kalousek I., Brodská B., Otevřelová P., Roselová P.
Jazyk angličtina Země Velká Británie
Grantová podpora
NR7998
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Zdroj
- MeSH
- apoptóza účinky léků MeSH
- daktinomycin aplikace a dávkování farmakologie MeSH
- down regulace MeSH
- financování organizované MeSH
- lidé MeSH
- lymfocyty účinky léků MeSH
- messenger RNA metabolismus MeSH
- mitochondrie metabolismus MeSH
- nádorový supresorový protein p53 metabolismus MeSH
- polymerázová řetězová reakce s reverzní transkripcí MeSH
- poškození DNA účinky léků MeSH
- proteiny regulující apoptózu metabolismus MeSH
- protinádorová antibiotika aplikace a dávkování farmakologie MeSH
- protoonkogenní proteiny c-bcl-2 metabolismus MeSH
- protoonkogenní proteiny metabolismus MeSH
- průtoková cytometrie MeSH
- ribozomální DNA účinky léků MeSH
- upregulace účinky léků MeSH
- viabilita buněk MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- western blotting MeSH
- Check Tag
- lidé MeSH
We have examined the ability of actinomycin D to induce apoptosis in human peripheral blood lymphocytes. Run-On assays were performed to specify the primary molecular damage, reverse transcription-PCR, Western blots and flow cytometry studies were performed to ascertain which proteins of the apoptosis machinery were affected to cause actinomycin D-induced cell death. Expression of 23 apoptosis-related genes was investigated. The down-regulation of ribosomal RNA synthesis caused by actinomycin D induced a mitochondria-dependent apoptosis. Although the expression of the majority of examined genes remained indifferent against actinomycin D activity, the cellular level of p53 protein increased, subsequently upregulating both Puma mRNA and protein. Puma-mediated mitochondrial apoptosis was accompanied by nucleolin cleavage and Bcl-2 mRNA destabilization. The stability of the cellular level of Bcl-2 protein independent of a mRNA decrease suggests that protection of Bcl-2 protein against proteasomal degradation can moderate the apoptotic process. In peripheral blood lymphocytes cultured in vitro, the apoptosis induced by a low concentration of actinomycin D (10 nmol/l) is dependent on p53 and Puma activation. This apoptotic pathway is demonstrated in peripheral blood lymphocytes for the first time. A different apoptotic pathway induced in peripheral blood lymphocytes using this drug has, however, been previously revealed by other authors. The combination of cell specificity and dose-dependent effects can likely play a decisive role in apoptosis observed in peripheral blood lymphocytes after genotoxic drug application.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10001019
- 003
- CZ-PrNML
- 005
- 20130820110029.0
- 008
- 100118s2007 xxk e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kalousek, Ivan $7 xx0070918
- 245 10
- $a Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes / $c Kalousek I., Brodská B., Otevřelová P., Roselová P.
- 314 __
- $a Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128-20 Prague, Czech Republic. kal@uhkt.cz
- 520 9_
- $a We have examined the ability of actinomycin D to induce apoptosis in human peripheral blood lymphocytes. Run-On assays were performed to specify the primary molecular damage, reverse transcription-PCR, Western blots and flow cytometry studies were performed to ascertain which proteins of the apoptosis machinery were affected to cause actinomycin D-induced cell death. Expression of 23 apoptosis-related genes was investigated. The down-regulation of ribosomal RNA synthesis caused by actinomycin D induced a mitochondria-dependent apoptosis. Although the expression of the majority of examined genes remained indifferent against actinomycin D activity, the cellular level of p53 protein increased, subsequently upregulating both Puma mRNA and protein. Puma-mediated mitochondrial apoptosis was accompanied by nucleolin cleavage and Bcl-2 mRNA destabilization. The stability of the cellular level of Bcl-2 protein independent of a mRNA decrease suggests that protection of Bcl-2 protein against proteasomal degradation can moderate the apoptotic process. In peripheral blood lymphocytes cultured in vitro, the apoptosis induced by a low concentration of actinomycin D (10 nmol/l) is dependent on p53 and Puma activation. This apoptotic pathway is demonstrated in peripheral blood lymphocytes for the first time. A different apoptotic pathway induced in peripheral blood lymphocytes using this drug has, however, been previously revealed by other authors. The combination of cell specificity and dose-dependent effects can likely play a decisive role in apoptosis observed in peripheral blood lymphocytes after genotoxic drug application.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a protinádorová antibiotika $x aplikace a dávkování $x farmakologie $7 D000903
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a proteiny regulující apoptózu $x metabolismus $7 D051017
- 650 _2
- $a western blotting $7 D015153
- 650 _2
- $a viabilita buněk $7 D002470
- 650 _2
- $a poškození DNA $x účinky léků $7 D004249
- 650 _2
- $a ribozomální DNA $x účinky léků $7 D004275
- 650 _2
- $a daktinomycin $x aplikace a dávkování $x farmakologie $7 D003609
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a down regulace $7 D015536
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfocyty $x účinky léků $7 D008214
- 650 _2
- $a mitochondrie $x metabolismus $7 D008928
- 650 _2
- $a protoonkogenní proteiny $x metabolismus $7 D011518
- 650 _2
- $a protoonkogenní proteiny c-bcl-2 $x metabolismus $7 D019253
- 650 _2
- $a messenger RNA $x metabolismus $7 D012333
- 650 _2
- $a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
- 650 _2
- $a nádorový supresorový protein p53 $x metabolismus $7 D016159
- 650 _2
- $a upregulace $x účinky léků $7 D015854
- 700 1_
- $a Brodská, Barbora $7 xx0161159
- 700 1_
- $a Otevřelová, Petra. $7 xx0238631
- 700 1_
- $a Roselová, Pavla. $7 _AN044737
- 773 0_
- $w MED00179775 $t Anticancer Drugs $g Roč. 18, č. 7 (2007), s. 763-772 $x 0959-4973
- 910 __
- $y 8 $a ABA008 $b x
- 990 __
- $b ABA008 $a 20100114083259
- 991 __
- $a 20130820110545 $b ABA008
- 999 __
- $a ok $b bmc $g 703747 $s 566189
- BAS __
- $a 3
- BMC __
- $a 2007 $b 18 $c 7 $d 763-772 $m Anticancer Drugs $x MED00179775
- GRA __
- $a NR7998 $p MZ0
- LZP __
- $a 2010-b1/vtme